A 6-month, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of USPlus DERM to Promote Hair Growth in Men and Women With Self-perceived Thinning Hair.

The registered record

Accession number

NCT06920758

Lead sponsor

Ablon Skin Institute Research Center (other)

Collaborators

U.S. Nutraceuticals, Inc. dba Valensa International

Registered condition naming hair loss

Thinning Hair

Interventions

• Dietary supplementUSPlus DERM Bioactive Fatty Acids 160 mg Softgels
• OtherPlacebo softgel

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type

interventional

Phase

Not applicable

Allocation

randomized

Masking

triple

Primary purpose

treatment

Enrolment

60 participants (actual)

Sites

1 location in United States

What it measures

1. Change in terminal hair counts from Baseline to Day 180 using the Canfield HairMetrix system.

   Time frame: Baseline to Day 180

2. Change in vellus hair counts from Baseline to Day 180 using the Canfield HairMetrix system.

   Time frame: Baseline to Day 180

3. Change in total hair counts from Baseline to Day 180 using the Canfield HairMetrix system.

   Time frame: Baseline to Day 180

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex

all

Age

25 Years to 65 Years

Healthy volunteers

accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start

16 December 2024 (actual)

Primary completion

September 2025 (estimated)

Study completion

September 2025 (estimated)

First posted

10 April 2025 (actual)

Last update posted

10 April 2025 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: a primary completion registered as 2025-09 is a month, and rendering it as 1 September 2025 would invent a day the sponsor did not register.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Diffuse Thinning vs. Pattern Baldness: How to Tell the Difference (2026 Guide)How to Tell If You're Going Bald: Early Signs & Self-Assessment Guide (2026)

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT06920758 on ClinicalTrials.gov · All 157 trials in the pipeline